Trump Administration Ends Medicare Drug Subsidy, Raising Premium Concerns for Millions
By Lee Bond I SCN
The Trump administration will end a temporary federal program that helped control premiums for Medicare prescription drug plans, potentially leaving millions of older Americans paying more for coverage beginning in 2027.
WASHINGTON — The Trump administration is ending a Medicare subsidy program that helped prevent sharp premium increases for people enrolled in stand-alone prescription drug plans.
The Medicare Part D Premium Stabilization Demonstration will expire after 2026, the Centers for Medicare and Medicaid Services confirmed. The temporary program provided federal payments to insurers as the Medicare drug benefit underwent major changes introduced under the Inflation Reduction Act.
Approximately 25 million people receive drug coverage through stand-alone Medicare Part D plans and could be affected when the assistance ends.
Why the subsidy was introduced
The Biden administration launched the program in 2024 after insurers warned that changes to Medicare Part D could produce significant premium increases.
Those changes included a new annual limit on how much beneficiaries must pay out of pocket for covered prescription drugs. While the cap provided greater protection to patients with high medication costs, it also shifted more of the financial responsibility to insurance companies.
The subsidy was intended to give insurers time to adjust while preventing those additional costs from being passed immediately to beneficiaries through substantially higher monthly premiums.
In 2026, the program reduced average premiums by approximately $16 per month, helping bring the average stand-alone Part D premium to about $36. The federal government is expected to spend roughly $3.6 billion on the assistance during the year.
How much could premiums increase?
The exact impact will depend on the beneficiary’s insurer, location and selected plan. Final premiums for 2027 are expected to become available before Medicare’s annual open-enrollment period.
CMS Administrator Dr. Mehmet Oz said most beneficiaries would experience relatively modest increases and that affordable options would remain available. Administration estimates suggest many enrollees could see increases of less than $10 per month.
However, independent projections indicate that some beneficiaries may face larger increases. Around 45% of stand-alone Part D members could see monthly premiums rise by between $11 and $20, while approximately 30% could face increases below $10. Some plans could maintain or reduce their rates.
Premium changes could vary significantly between plans, making it especially important for beneficiaries to review their coverage rather than automatically renewing it.
Administration calls program an insurer bailout
The Trump administration argues that the temporary payments are no longer necessary because insurance companies now have enough experience to estimate the costs associated with the redesigned Medicare drug benefit.
Officials have also criticized the program for directing billions of federal dollars to insurance companies. Oz described the payments as a bailout that may have weakened insurers’ incentive to control premiums.
CMS said its review of insurers’ proposed 2027 rates showed that companies should now be able to price their plans without additional government support.
Critics dispute that assessment, warning that ending the assistance could transfer costs from the federal government to older Americans living on fixed incomes.
Drug protections will remain
Ending the premium subsidy does not repeal Medicare’s other prescription drug protections.
Beneficiaries will continue to receive the annual cap on out-of-pocket spending for medicines covered by their plans. Other provisions, including negotiated prices for selected high-cost medications and limits on insulin expenses, are separate from the stabilization program.
The biggest immediate change is therefore expected to involve the monthly price of insurance coverage rather than the elimination of the underlying Part D benefit.
However, beneficiaries may also encounter changes to deductibles, pharmacy networks or lists of covered medications as insurers redesign their plans for 2027.
Could more seniors move to Medicare Advantage?
Higher prices for stand-alone drug plans could encourage more beneficiaries to consider Medicare Advantage, which often combines hospital, medical and prescription drug coverage under one policy.
Medicare Advantage plans frequently advertise low or zero additional premiums, but they may also impose provider networks, prior authorization requirements and other restrictions not found in traditional Medicare.
Experts caution beneficiaries against choosing a plan based only on its monthly premium. A less expensive policy could ultimately cost more when prescription coverage, doctors, hospitals and other expenses are considered.
What beneficiaries should do
Medicare recipients should carefully examine their Annual Notice of Change, which insurers send before open enrollment. The document explains changes to premiums, deductibles, covered drugs and pharmacy arrangements.
Beneficiaries should confirm that:
- Their prescriptions remain covered.
- Their preferred pharmacies remain in the plan’s network.
- Their doctors and hospitals are available under any Medicare Advantage alternative.
- The total annual cost is affordable, not merely the advertised premium.
Medicare’s annual open-enrollment period generally gives beneficiaries an opportunity to compare plans and change their coverage for the following year.
Political debate intensifies
Democrats have criticized the decision as another action that could raise healthcare costs for seniors. The administration maintains that the subsidy primarily benefited insurers and that competition will preserve affordable choices.
The full political and financial effect may become clearer when insurers publish their 2027 rates in the fall, placing the issue before voters ahead of the midterm elections.